Incidence and risk factors for coronavirus disease 2019-associated pulmonary aspergillosis using administrative claims data.

IF 4.1 2区医学 Q1 DERMATOLOGY Mycoses Pub Date : 2024-08-01 DOI:10.1111/myc.13773

Waki Imoto, Yasutaka Ihara, Takumi Imai, Ryota Kawai, Koichi Yamada, Yukihiro Kaneko, Ayumi Shintani, Hiroshi Kakeya

{"title":"Incidence and risk factors for coronavirus disease 2019-associated pulmonary aspergillosis using administrative claims data.","authors":"Waki Imoto, Yasutaka Ihara, Takumi Imai, Ryota Kawai, Koichi Yamada, Yukihiro Kaneko, Ayumi Shintani, Hiroshi Kakeya","doi":"10.1111/myc.13773","DOIUrl":null,"url":null,"abstract":"Background: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is one of the noticeable complications of COVID-19 and its incidence varies widely. In Japan, research on the incidence, risk factors and mortality associated with CAPA is limited.Objectives: This study aimed to explore the incidence and potential risk factors for CAPA in patients with severe or critical COVID-19 and evaluate the relationship between CAPA and mortality of patients with severe or critical COVID-19.Methods: We investigated the incidence of CAPA in patients with severe and critical COVID-19 using administrative claims data from acute care hospitals in Japan. We employed multivariable regression models to explore potential risk factors for CAPA and their contribution to mortality in patients with severe and critical COVID-19.Results: The incidence of CAPA was 0.4%-2.7% in 33,136 patients with severe to critical COVID-19. Age, male sex, chronic lung disease, steroids, immunosuppressants, intensive care unit admission, blood transfusion and dialysis were potential risk factors for CAPA in patients with severe to critical COVID-19. CAPA was an independent factor associated with mortality.Conclusions: CAPA is a serious complication in patients with severe and critical COVID-19 and may increase mortality.","PeriodicalId":18797,"journal":{"name":"Mycoses","volume":"67 8","pages":"e13773"},"PeriodicalIF":4.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycoses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/myc.13773","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is one of the noticeable complications of COVID-19 and its incidence varies widely. In Japan, research on the incidence, risk factors and mortality associated with CAPA is limited.

Objectives: This study aimed to explore the incidence and potential risk factors for CAPA in patients with severe or critical COVID-19 and evaluate the relationship between CAPA and mortality of patients with severe or critical COVID-19.

Methods: We investigated the incidence of CAPA in patients with severe and critical COVID-19 using administrative claims data from acute care hospitals in Japan. We employed multivariable regression models to explore potential risk factors for CAPA and their contribution to mortality in patients with severe and critical COVID-19.

Results: The incidence of CAPA was 0.4%-2.7% in 33,136 patients with severe to critical COVID-19. Age, male sex, chronic lung disease, steroids, immunosuppressants, intensive care unit admission, blood transfusion and dialysis were potential risk factors for CAPA in patients with severe to critical COVID-19. CAPA was an independent factor associated with mortality.

Conclusions: CAPA is a serious complication in patients with severe and critical COVID-19 and may increase mortality.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用行政报销数据研究2019年冠状病毒病相关肺曲霉菌病的发病率和风险因素。

背景：冠状病毒病 2019（COVID-19）相关肺曲霉菌病（CAPA）是 COVID-19 的明显并发症之一，其发病率差异很大。在日本，对与 CAPA 相关的发病率、风险因素和死亡率的研究十分有限：本研究旨在探讨重度或危重 COVID-19 患者 CAPA 的发病率和潜在风险因素，并评估 CAPA 与重度或危重 COVID-19 患者死亡率之间的关系：我们利用日本急诊医院的行政报销数据调查了重度和危重 COVID-19 患者的 CAPA 发生率。我们采用多变量回归模型探讨了CAPA的潜在风险因素及其对重症和危重COVID-19患者死亡率的影响：结果：在 33 136 名重度和危重 COVID-19 患者中，CAPA 的发生率为 0.4%-2.7%。年龄、男性、慢性肺部疾病、类固醇、免疫抑制剂、入住重症监护室、输血和透析是重症和危重症COVID-19患者发生CAPA的潜在风险因素。CAPA是与死亡率相关的一个独立因素：结论：CAPA是重度和危重COVID-19患者的一种严重并发症，可能会增加死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Mycoses 医学-皮肤病学

CiteScore

10.00

自引率

8.20%

发文量

143

审稿时长

6-12 weeks

期刊介绍： The journal Mycoses provides an international forum for original papers in English on the pathogenesis, diagnosis, therapy, prophylaxis, and epidemiology of fungal infectious diseases in humans as well as on the biology of pathogenic fungi. Medical mycology as part of medical microbiology is advancing rapidly. Effective therapeutic strategies are already available in chemotherapy and are being further developed. Their application requires reliable laboratory diagnostic techniques, which, in turn, result from mycological basic research. Opportunistic mycoses vary greatly in their clinical and pathological symptoms, because the underlying disease of a patient at risk decisively determines their symptomatology and progress. The journal Mycoses is therefore of interest to scientists in fundamental mycological research, mycological laboratory diagnosticians and clinicians interested in fungal infections.